{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:50:22Z","timestamp":1767790222388,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To quantify concordance between single-time-point (STP) and multiple-time-point (MTP) dosimetry for organs-at-risk (OARs) and lesions in\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-I&amp;T.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirteen men with metastatic castration-resistant prostate cancer underwent quantitative SPECT\/CT at ~20, ~48, and ~120\u2009h posttherapy. Lesions &lt;3.0 cc were excluded. Time-activity curves (TACs) were fit with automatic model-order selection (parameters \u2264 data points); accepted fits required\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      &gt; 0.90. STP activity\u2013time integrals were estimated with the H\u00e4nscheid formalism. Agreement metrics included paired median differences, Lin\u2019s concordance, and Bland\u2013Altman bias\/limits of agreement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For OARs, STP at ~48\u2009h matched MTP with minimal bias (parotids \u0394 = 0.00 Gy\/GBq,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.475; kidneys \u0394 = 0.02,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.157). Lesion concordance improved with later imaging (STP2\u2013STP3), whereas ~20\u2009h STP underestimated lesion dose coefficients (all lesions \u0394 = +0.36 Gy\/GBq; +57.4%). TAC modeling favored mono-exponential kinetics in most lesions (83%) and kidneys, with mixed behavior in parotids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A single quantitative scan at ~48\u2009h provides OAR dosimetry concordant with MTP, while lesion estimates are best captured at ~48\u2013120\u2009h. Early STP imaging (~20\u2009h) should not be used alone for lesions. Findings support a pragmatic, concordance-oriented dosimetry workflow for routine\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-I&amp;T care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002076","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:02:06Z","timestamp":1762250526000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Concordance between single-time-point and multiple-time-point dosimetry in 177Lu-PSMA-I&amp;T therapy for metastatic castration-resistant prostate cancer"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1631","authenticated-orcid":false,"given":"Nathaly","family":"Barbosa","sequence":"first","affiliation":[{"name":"Unit of Diagnostic Imaging and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-4273","authenticated-orcid":false,"given":"Carlos","family":"Granados","sequence":"additional","affiliation":[{"name":"Unit of Diagnostic Imaging and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-0018","authenticated-orcid":false,"given":"Edwin","family":"Pulido","sequence":"additional","affiliation":[{"name":"Institute of Research and Education, Centro de Tratamiento e Investigaci\u00f3n sobre C\u00e1ncer Luis Carlos Sarmiento Angulo (CTIC), Bogot\u00e1, Cundinamarca, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4493-5222","authenticated-orcid":false,"given":"Clarena","family":"Zuluaga","sequence":"additional","affiliation":[{"name":"Unit of Diagnostic Imaging and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges.","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"MIRD pamphlet no. 26: Joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy.","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J Nucl Med"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-023-06226-z","article-title":"EANM enabling guide: how to improve the accessibility of clinical dosimetry.","volume":"50","author":"Gear","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-024-00658-8","article-title":"A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?","volume":"11","author":"Vergnaud","year":"2024","journal-title":"EJNMMI Phys"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177 Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions.","volume":"58","author":"Okamoto","year":"2017","journal-title":"J Nucl Med"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13153884","article-title":"Streamlined schemes for dosimetry of 177Lu-labeled PSMA targeting radioligands in therapy of prostate cancer.","volume":"13","author":"Kurth","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-021-00385-4","article-title":"Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy.","volume":"8","author":"Rosar","year":"2021","journal-title":"EJNMMI Phys"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1002\/mp.13789","article-title":"Dose point kernels for 2,174 radionuclides.","volume":"46","author":"Graves","year":"2019","journal-title":"Med Phys"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days.","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","article-title":"Feasibility of single-time-point dosimetry for radiopharmaceutical therapies.","volume":"62","author":"Hou","year":"2021","journal-title":"J Nucl Med"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2967\/jnumed.122.264594","article-title":"Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy.","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-016-0172-0","article-title":"Quantitative accuracy of 177Lu SPECT reconstruction using different compensation methods: phantom and patient studies.","volume":"6","author":"Hippel\u00e4inen","year":"2016","journal-title":"EJNMMI Res"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-020-0278-3","article-title":"Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT\/CT systems.","volume":"7","author":"Peters","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R19-20260107","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/acm2.12991","article-title":"177Lutetium SPECT\/CT: Evaluation of collimator, photopeak and scatter correction.","volume":"21","author":"Huizing","year":"2020","journal-title":"J Appl Clin Med Phys"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.118.211094","article-title":"Characterization of noise and resolution for quantitative 177 Lu SPECT\/CT with XSPECT quant.","volume":"60","author":"Tran-Gia","year":"2019","journal-title":"J Nucl Med"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-023-00529-8","article-title":"Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT\/CT acquisition.","volume":"10","author":"Resch","year":"2023","journal-title":"EJNMMI Phys"},{"key":"R22-20260107","first-page":"1","article-title":"Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points.","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R23-20260107","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-020-00311-0","article-title":"Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry.","volume":"7","author":"Rinscheid","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- And tissue-specific dose factors.","volume":"61","author":"Jackson","year":"2020","journal-title":"J Nucl Med"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmp.2022.06.002","article-title":"Is a single late SPECT\/CT based kidney 177Lu-dosimetry superior to hybrid dosimetry with sequential multiple time-point whole-body planar scans in combination with an early SPECT\/CT?","volume":"100","author":"Beykan","year":"2022","journal-title":"Phys Med"},{"key":"R26-20260107","doi-asserted-by":"crossref","first-page":"103192","DOI":"10.1016\/j.ejmp.2023.103192","article-title":"Time-activity data fitting in molecular radiotherapy: methodology and pitfalls.","volume":"117","author":"Ivashchenko","year":"2024","journal-title":"Phys Med"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-023-00561-8","article-title":"Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm.","volume":"10","author":"Staanum","year":"2023","journal-title":"EJNMMI Phys"},{"key":"R29-20260107","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes.","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"R30-20260107","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177 Lu]Lu-PSMA\u2013targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis.","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"},{"key":"R31-20260107","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R32-20260107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-021-00397-0","article-title":"A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT\/CT imaging performed within the MRTDosimetry project.","volume":"8","author":"Tran-Gia","year":"2021","journal-title":"EJNMMI Phys"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:01:04Z","timestamp":1767772864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002076","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"2025-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}